Immunoprecise Antibodies Ltd (IPA) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Jan 31 2026 to Jan 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Immunoprecise Antibodies Ltd   (NASDAQ: IPA)


Immunoprecise Antibodies Ltd's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Immunoprecise Antibodies Ltd's ROI in the third quarter of 2026?
Immunoprecise Antibodies Ltd recorded a cumulative net loss of $-9 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -43.33%.

Within the Healthcare sector 604 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2025 from to 4140.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jan 31 2026)
III. Quarter		 (Oct 31 2025)
II. Quarter		 (Jul 31 2025)
I. Quarter		 (Apr 30 2025)
IV. Quarter		 (Jan 31 2025)
III. Quarter
Y / Y Investment Change TTM -47.03 % -44.99 % -29.99 % -22.87 % -5.2 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 26 15 17 26 31
Return On Investment (TTM) -43.33 % -96.09 % -142.12 % -123.33 % -95.88 %
IPA's Overall Ranking # 4140 # # # #
Seq. Investment Change TTM -6 % -20.75 % -12.6 % -18.63 % -2.38 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -9 -21 -40 -40 -38

IPA Company Profile >> Back to IPA Roi Comparisons >> See Annual IPA Return On Investment



Return On Investment IPA's Ranking
Within: No.
Industry # 259
Sector # 605
Overall # 4140

Return On Investment Statistics
High Average Low
-52.4 %
-52.4 %
-52.4 %
(Apr 30 2024)  



  News about Immunoprecise Antibodies Ltd Return on Investment ROI

ImmunoPrecise Antibodies to Unveil Q1 Fiscal 2025 Results Amid Promising AI-Driven Biotherapeutic Developments

September 9, 2024

In a significant announcement that underscores its position in the burgeoning field of artificial intelligence and biotherapeutics, ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) revealed plans to report its financial results for the first quarter of fiscal year 2025 on September 16, 2024. Based in Victoria, British Columbia, the company is recognized for its pioneering use of AI technology in biotherapeutic research and development.The scheduled conference call, set to commence at 10:30 am Eastern Time, will provide an opportunity for stakeholders, analysts, and the public to gain insights into the company’s financial health and strategic initiatives. Prior to the call, ImmunoPrecise is expected to disseminate a press release detailing its financial performance alongside key business highlights from the quarter.

Pioneering the Future of Cancer Treatment ImmunoPrecise Antibodies Utilizes LENSai Technology to Engineer Targeted An...

August 19, 2024

In a remarkable leap forward for the biotechnology sector, ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an innovative leader in AI-driven biotherapeutics, has announced a groundbreaking development in the engineering of antibodies specifically designed to tackle challenging oncology targets. Utilizing its patented LENSai technology, the company has successfully harnessed computational simulations to create antibodies that exhibit high specificity for elusive tumor proteins within the Tumor Microenvironment (TME).The advent of LENSai technology heralds a new era in antibody development. Traditionally, the process of engineering antibodies has been labor-intensive and time-consuming, often relying on trial and error in laboratory settings. In contrast, LENSai facilitates the design of antibodies in silico via sophisticated computational models that simulate interactions between antibodies and their targets with unprecedented precision. This innovative approach not only accelerates the development timeline but also enhances the likelihood of producing highly effective therapeutic agents.





Financial Statements
Immunoprecise Antibodies Ltd's III. Quarter Investments $ 26 Millions IPA's Balance sheet
Immunoprecise Antibodies Ltd's III. Quarter Income $ -3 Millions Quarterly IPA's Income Statement
IPA's Income by Division See IPA's Income by Division


IPA Annual Return On Investment (Apr 30 2025)
2025		 (Apr 30 2024)
2024		 (Apr 30 2023)
2023		 (Apr 30 2022)
2022		 (Apr 30 2020)
2021
Total Investments in Millions 26 40 55 66 14
Y / Y Investment Growth -35.41 % -27.86 % -16.45 % 374.29 % -
Net Income in Millions -22 -21 -20 -13 -4
Y / Y Net Income Growth - - - - -
Annual Return On Investment -84.58 % -52.4 % -36.94 % -20.21 % -26.64 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
IPA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for IPA's Competitors
Subscribers only: Roi for Immunoprecise Antibodies Ltd's Suppliers
Subscribers only: Return On Investment for IPA's Customers

Other Ratios
IPA's Roa IPA's Inventory Turnover Ratio IPA's Growth Rates IPA's Dividend Statistics
IPA's Profitability Ratios IPA's Asset Turnover Ratio IPA's Dividend Growth
IPA's Roe IPA's Valuation Ratios IPA's Financial Strength Ratios IPA's Dividend Payout Ratio



Companies with similar Return On Investment at Jan 31 2026, within Healthcare Sector ROI

Date modified: 2026-09-18T17:05:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.